BioXcel Therapeutics shares are trading lower after the company released topline results from TRANQUILITY II Phase 3 trial of BXCL501 for acute treatment of Alzheimer's Disease-related agitation.
Portfolio Pulse from Benzinga Newsdesk
BioXcel Therapeutics has released topline results from its TRANQUILITY II Phase 3 trial of BXCL501 for acute treatment of Alzheimer's Disease-related agitation. The company's shares are trading lower following the announcement.
June 29, 2023 | 12:24 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
BioXcel Therapeutics' stock is trading lower after the company announced topline results from its Phase 3 trial of BXCL501.
The company's shares are trading lower following the announcement of the topline results from its Phase 3 trial. This suggests that the market may have had negative reactions to the results, which could potentially impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100